Canadian Immunization Committee recommends 4 months between COVID doses
The efficacy of the vaccine from the first dose will be closely monitored and the decision to delay the second dose will be continuously evaluated based on surveillance and efficacy data and post-implementation study designs, the group wrote. .
Efficacy against the variants of concern will also be closely monitored and recommendations may need to be revised, he said, adding that there is currently no evidence that a longer interval will affect emergence. variants.
The updated guidelines apply to the three vaccines currently approved for use in Canada.
The committee’s recommendation came hours after the Atlantic Coast Province of Newfoundland and Labrador said it would extend the interval between the first and second dose to four months, and days after that. health officials in the Pacific Coast Province of British Columbia have announced they are doing so.
Manitoba and Quebec also said on Wednesday they would delay second doses. And the Ontario health minister has said Ontario will speed up the rollout of its vaccines quickly.
Earlier Wednesday, Trudeau said any change in public health guidelines regarding the timing of the two doses could affect the speed of vaccine deployment in Canada, as could the approval of more vaccines like Johnson and Johnson.
The provinces of Canada administer health care in the country, so it is ultimately up to the provinces.
Dr Brad Wouters, executive vice president of science and research at the University Health Network, questioned this recommendation. No one in the world has spent 4 months between doses. These are RNA vaccines never used before. We should use evidence to make decisions. Canada is conducting a demographic experiment, Wouters tweeted.
And Mona Nemer, the federal government’s chief science adviser, also said this week that the plan amounts to a population-level experiment and that the data provided so far by Moderna and Pfizer-BioNTech is based on an interval three to four weeks between doses. .
But British Columbia provincial health officer Dr Bonnie Henry said manufacturers have structured their clinical trials this way to get the vaccines to market as quickly as possible, but research in British Columbia, in Quebec, Israel and the United Kingdom showed it first. the doses are very effective.